Evidence map›Paper›PMID 35633412›Full record

ArticleJournal of patient-reported outcomes2022

Content validity of a newly developed observer-reported measure for pediatric asthma in children aged 2-5 years.

Yi Zhang, Jennifer L Clegg, Shannon Keith, Shehan McFadden, Tara Symonds, Rajesh Kumar, Asif H Khan, Siddhesh Kamat, Jingdong Chao

Open access · goldAbstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Yi ZhangRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Jennifer L CleggClinical Outcomes Assessment, Clinical Outcomes Solutions, 53 W Jackson Blvd, Suite 1150, Chicago, IL, 60604, USA. jennifer.clegg@clinoutsolutions.com.ORCID http://orcid.org/0000-0002-8153-5351
Shannon KeithClinical Outcomes Assessment, Clinical Outcomes Solutions, 53 W Jackson Blvd, Suite 1150, Chicago, IL, 60604, USA.
Shehan McFaddenClinical Outcomes Assessment, Clinical Outcomes Solutions, 53 W Jackson Blvd, Suite 1150, Chicago, IL, 60604, USA.
Tara SymondsClinical Outcomes Solutions, Folkestone, UK.
Rajesh KumarLurie Children's Hospital, Chicago, IL, USA.
Asif H KhanSanofi, Chilly-Mazarin, France.
Siddhesh KamatRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Jingdong ChaoRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Health Outcomes Solutions (United States) · USRegeneron (United States) · USLurie Children's Hospital · USSanofi (France) · FR

Funding

Regeneron Pharmaceuticals Not appplicableSanofi Not appplicable
6 · The paper itself

Abstract

backgroundAn observer-reported outcome (ObsRO) measure assessing both symptom control and health-related quality of life (HRQoL) in children with asthma younger than 6 years is lacking. The objective of this study was to evaluate the content validity of the Pediatric Asthma Questionnaire (PAQ), a newly developed 6-item ObsRO measure for caregivers of children aged 2-5 years diagnosed with asthma.

resultsIn-depth, qualitative interviews were conducted with 15 parents or caregivers. The first part of the interview was an open-ended discussion whereby participants were asked to describe their observations of their child's asthma symptoms and HRQoL impacts followed by a cognitive debriefing of a draft version of the PAQ. The most frequently reported symptoms were coughing (n = 15, 100%), wheezing (n = 14, 93%), and trouble breathing (n = 10, 67%). Overall, participants found the PAQ easy to complete and relevant to their child's experience with asthma, with most reporting the instructions, response scales, and recall period for the items to be appropriate. The majority of participants (93%) believed they could accurately report on the items included in the PAQ based on their observations of their child's asthma symptoms and impacts, or reliably get the information from the child's teacher, school, or caregiver when their child was not in their presence. One item was modified based on feedback about the phrase "oral steroids" to clarify modes of administration. A few other minor changes were incorporated into the PAQ following suggestions from participants, including replacing the phrase "how often" with "how many days" in one of the items to improve clarity and overall consistency with the response options.

conclusionQualitative data support the content validity of the PAQ as a fit-for-purpose and well-understood 6-item observer-reported outcome measure to evaluate both symptoms and asthma-specific HRQoL impacts experienced by pediatric asthma patients aged 2-5 years for use in clinical and real-world studies.

Indexed as

AsthmaContent validityHealth-related quality of lifeHRQoLObserver-reported outcomeObsROPAQPatient-reported outcomePediatricPediatric Asthma QuestionnairePRO

Identifiers

PMID35633412
PMCPMC9148329
OpenAlexW4281768105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.